NewAmsterdam Pharma (NAMS) Cash from Financing Activities (2023 - 2026)

NewAmsterdam Pharma has disclosed Cash from Financing Activities across 4 years of filings, most recently posting $11.1 million for Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at $11.1 million, up 69.73% year-over-year; the trailing twelve-month figure through Mar 2026 was $34.1 million (down 92.72% YoY), and the FY2025 annual result was $29.5 million, down 95.52% from the prior year.
• Cash from Financing Activities came in at $11.1 million for Q1 2026 at NewAmsterdam Pharma, down from $13.7 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $456.6 million in Q4 2024 to a low of $58000.0 in Q3 2024.
• The 4-year median for Cash from Financing Activities is $6.1 million (2023), against an average of $59.1 million.
• Peak annual rise in Cash from Financing Activities reached 10058.62% in 2025, while the deepest fall reached 97.0% in 2025.
• NewAmsterdam Pharma's Cash from Financing Activities stood at $186000.0 in 2023, then jumped by 245389.78% to $456.6 million in 2024, then tumbled by 97.0% to $13.7 million in 2025, then dropped by 19.14% to $11.1 million in 2026.
• The last three Cash from Financing Activities figures came in at $11.1 million (Q1 2026), $13.7 million (Q4 2025), and $5.9 million (Q3 2025), per Business Quant data.